Basel, Switzerland, 18. March 2020 – The Board of Directors of Medartis Holding AG (SIX: MED), a leading manufacturer and provider of medical devices for surgical fixation of bone fractures, proposes Marco Gadola for election as a member of the Board of Directors at the Annual General Meeting on 17 April 2020. With his proven expertise and leadership experience in the international medical technology market, Marco Gadola will further strengthen the Board of Directors and support the company on its growth path.
The Board of Directors of Medartis Holding AG has decided to propose Marco Gadola for election as an additional independent member of the Board of Directors at the Annual General Meeting on 17 April 2020. Following his election, he is to become a member of the Finance and Audit Committee. All current members of the Board of Directors and Chairman Dr. h.c. Thomas Straumann will stand for reelection at the 2020 Annual General Meeting.
From 2013 until the end of 2019, Marco Gadola was Chief Executive Officer of the Straumann Group, a leading company in the dental market. From 2006 until 2008, he was the Straumann Group’s Chief Financial Officer and a member of its Executive Management Board. In the time between these two positions, he was Chief Executive Officer Asia Pacific and Chief Financial and Information Technology Officer at Panalpina Group, where he worked for five years. Prior to this, he was Chief Financial Officer at Hero and held a number of leadership positions at Hilti. He began his career at UBS in corporate finance and at Novartis as a senior auditor. Marco Gadola was born in 1963 and is a Swiss and French citizen. He holds a master’s in business administration and economics from the University of Basel and completed programs at the London School of Economics and IMD Management School in Lausanne.
Marco Gadola is a member of the Board of Directors of the DKSH Group (nominated as Chairman), Medacta AG and Calida Group (Chairman). He has also been put forward for election as Member of the Board of Directors of the Straumann Group.
Dr. h.c. Thomas Straumann, Chairman of Medartis: “I am very pleased about the nomination of Marco Gadola as Member of the Board of Directors of Medartis. I am convinced that with his excellent knowledge of the market, his extensive international experience and his outstanding track record, he will make an important contribution to our Board and support the company as it continues on its growth path.”
Coronavirus: information about the Annual General Meeting of Medartis Holding AG In order to protect the health of all concerned and in view of the Federal Council’s measures to combat the coronavirus (COVID-19), which were updated on 16 March 2020, the General Meeting will be held without an audience on 17 April 2020. In accordance with COVID-19 Regulation 2, Art. 6a para. 1 lit. b, voting must be exercised via the independent proxy, Neovius AG.
The agenda items for the 2020 Annual General Meeting are scheduled to be published on the Medartis website on 23 March 2020 at www.medartis.com/investor-media-relations/#page-1095.
Head Corporate Services
Medartis Holding AG
Phone: +41 61 633 34 70
Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world’s leading manufacturers and providers of medical devices for surgical fixation of bone fractures for upper and lower extremities as well as for the craniomaxillofacial region. Medartis employs over 600 individuals across its 13 locations, with products offered in over 50 countries globally. Medartis is committed to providing surgeons and operating theater personnel with the most innovative titanium implants and instruments as well as best in class service. For more information, please visit www.medartis.com.
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. Further, neither the company nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained herein or of the views given or implied.